Verve Therapeutics Inc

NASDAQ:VERV  
13.39
-0.15 (-1.11%)
Regulatory, Earnings Announcements

Verve Therapeutics Announces Clearance Of First Verve-101 Clinical Trial Application And Outlines Global Clinical Development Strategy Reports First Quarter 2022 Financial Results

Published: 05/10/2022 10:42 GMT
Verve Therapeutics Inc (VERV) - Verve Therapeutics Announces Clearance of First Verve-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results.
Q1 Loss per Share $0.62.
Cash Runway Into 2024.
Q1 Earnings per Share View $-0.66 -- Refinitiv Ibes Data (analyst estimates).
Net Loss Was $0.62 Basic and Diluted Net Loss per Share, for Q1 of 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.65

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.70

More details on our Analysts Page.